(Philadelphia, PA) - Building on previous work,
researchers at the University of Pennsylvania School of
Medicine have found that deleting an inflammation enzyme
in a mouse model of heart disease slowed the development of atherosclerosis.
What's more, the composition of the animals’ blood vessels
showed that the disease process had not only slowed, but also stabilized.
This study points to the possibility of a new class of nonsteroidal
anti-inflammatory drugs (NSAIDs) that steer clear of heart-disease
risk and work to reduce it.
Senior author Garret FitzGerald, MD, Director of
the Institute for Translational Medicine and Therapeutics at Penn,
and colleagues report their findings this week in the online edition
of the Proceedings of the National Academy of Sciences.
NSAIDs like ibuprofen (Advil) and naproxen (Naprosyn) relieve pain
and inflammation by blocking the cyclooxygenases, or COX enzymes
(COX-1 and COX-2). These enzymes help make fats called prostaglandins.
COX-2 is the most important source of the two prostaglandins - PGE2
and prostacyclin - that mediate pain and inflammation. However,
COX-2-derived PGE2 and prostacyclin may also protect the heart,
and loss of this function - particularly suppression of prostacyclin
- explains the risk of heart attacks from NSAIDs that inhibit COX-2,
such as rofecoxib (Vioxx), valdecoxib (Bextra), and celecoxib (Celebrex).
The problems with COX-2 inhibitors have prompted the search for
alternative drug targets that suppress pain and inflammation yet
are safe for the cardiovascular system. One possibility is an enzyme
called mPGES-1, which converts PGH2 (a chemical product of COX-2)
into PGE2. Previous studies at other institutions in mice lacking
mPGES-1 suggest that inhibitors of this enzyme might retain much
of the effectiveness of NSAIDs in combating pain and inflammation.
However, unlike COX-2 inhibition or deletion, the Penn researchers
had found that mPGES-1 deletion did not elevate blood pressure or
predispose the mice to thrombosis. This work began to raise the
possibility that mPGES-1 inhibitors might even benefit the heart.
In the PNAS study, the researchers studied the impact of
deleting the mPGES-1 gene in mice predisposed to hardening of the
arteries. Removing the enzyme had a dramatic effect on the development
of the disease. "Both male and female mice slowed their development
of atherosclerosis," explains first author Miao Wang,
PhD, a postdoctoral fellow in the Penn Institute.
The composition of the blood vessels of the transgenic mice suggested
that the disease process had not only slowed, but also stabilized.
Collaborators Ellen Pure and Alicia Zukas at the Wistar Institute
examined the detailed structure of the diseased arteries. Deleting
mPGES-1 resulted in a dramatic change in the cellular constituents
of the atherosclerotic plaques seen in the transgenic mice. In the
absence of the enzyme, the diseased vessels were depleted of immune
cells called macrophages, which led to the predominance of vascular
smooth muscle cells in blood vessel walls. In turn, this led to
a switch in the form of collagen - a fibrous structure that contributes
to the fabric of plaques - to a more stable and benign form.
"It seems that it is the complete reverse of the mechanism
that creates problems for COX-2 inhibitors," says FitzGerald.
Mice lacking mPGES-1 boost their production of prostacyclin, the
major heart-protecting fat produced by COX-2. They do this by redirecting
prostacylcin to vascular smooth muscle cells. The same mechanism
explains the group's earlier findings on blood pressure and thrombosis.
"It remains to be determined whether specific inhibitors of
mPGES-1 can replicate the consequences of removing the gene"
explains FitzGerald, "And if so, whether these results will
translate from mice to humans."
In the meantime, these results, say the investigators, will fuel
interest in the possibility of a new class of "super NSAIDs,"
which may not just avoid the risk of heart disease, but also actually
work to diminish it.
Study co-authors are Yiqun Hui and Emanuela Riciotti, both from
Penn, as well as Alicia Zukas and Ellen Pure from the Wistar Institute,
Philadelphia. This research was funded by the National Heart, Lung,
and Blood Institute.
PENN Medicine is a $2.9 billion enterprise
dedicated to the related missions of medical education, biomedical
research, and high-quality patient care. PENN Medicine consists
of the University of Pennsylvania School of Medicine (founded in
1765 as the nation's first medical school) and the University of
Pennsylvania Health System.
Penn's School of Medicine is ranked #2 in the nation for receipt
of NIH research funds; and ranked #3 in the nation in U.S. News
& World Report's most recent ranking of top research-oriented
medical schools. Supporting 1,400 fulltime faculty and 700 students,
the School of Medicine is recognized worldwide for its superior
education and training of the next generation of physician-scientists
and leaders of academic medicine.
The University of Pennsylvania Health System includes three hospitals,
all of which have received numerous national patient-care honors [Hospital
of the University of Pennsylvania; Pennsylvania Hospital, the nation's
first hospital; and Penn Presbyterian Medical Center]; a faculty practice
plan; a primary-care provider network; two multispecialty satellite
facilities; and home care and hospice.